Report cover image

Gynaecology Drugs Market Report and Forecast 2025-2034

Publisher Expert Market Research
Published Jul 28, 2025
Length 350 Pages
SKU # EMAR20319775

Description

The global gynaecology drugs market size was valued at USD 28.54 Billion in 2024, driven by the rise in the geriatric population across the globe. The market size is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034 to achieve a value of USD 51.60 Billion by 2034.

Gynaecology Drugs: Introduction

The medications that are used by women when they are pregnant are called as gynaecology drugs. The most used gynaecology drugs are analgesics, antimetics, antacids, antimicrobials, antiemetics, antacids, antihistamines, antimicrobials, diuretics, hypnotics, and tranquilizers, among others. These drugs are used to treat certain disorders that occur during pregnancy. The gynaecology drugs are used in the treatment of medical issues with female reproductive system and during pregnancy and childbirth. Hormonal and non-hormonal therapies are the major kind of treatments that are provided in gynaecology drugs. Hormonal therapy is also one of those as it blocks, reduces, or adds hormones that stop the growth of the cancer cells which require the growth of hormones.

Global Gynaecology Drugs Market Analysis

The increasing investments by the key players of the market in the development and research procedures to develop personalized cancer vaccines, including gynaecology cancers, is one of the key factors which is contributing to the gynaecology drugs market growth. Some of them have even reached the trial phases before their final launch in the market. Increased use of genetic sequencing and precision medicine has been going on to develop new drug therapies and cancer treatments to decrease the rate of Gynaecology cancer.

Gynaecology Drugs Market Segmentations

The EMR’s report titled “Gynaecology Drugs Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Therapy Type
  • Hormonal Therapy
  • Non-Hormonal Therapy
Market Breakup by Indication
  • Gynaecology Cancers
  • Endometriosis
  • Female Infertility
  • Menopausal Disorder
  • Gynaecology Infections
  • Polycystic Ovary Syndrome (PCOS)
  • Contraception
  • Other Indication
Market by Route of Administration
  • Oral
  • Parenteral
  • Intravaginal
  • Others
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others
Market Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Research Institute
  • Home Healthcare
  • Others
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Global Gynaecology drugs Market Overview

The increasing number of women suffering from ovarian cancer is expected to favour the gynaecology drugs market expansion. The gynaecology drug market has been growing and is expected to grow in the coming years as well. Due to the increasing incidence of gynaecology cancer, the market is poised to witness robust growth in the coming years.

Gynaecology Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Amgen Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Allergan Plc
  • Bayer AG Financial Analysis
  • AbbVie Inc.
  • Lupin Pharmaceuticals Inc.
  • Therapeutics MD Inc.
  • Ferring Holding S.A.
  • Teva Pharmaceutical Industries Limited
  • Addex Therapeutics Ltd.
*Please Note:* The report will take 5 business days to complete, after order confirmation.

Table of Contents

350 Pages
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Gynaecology Drugs Market Overview
3.1 Global Gynaecology Drugs Market Historical Value (2018-2024)
3.2 Global Gynaecology Drugs Market Forecast Value (2025-2034)
4 Global Gynaecology Drugs Market Landscape
4.1 Global Gynaecology Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Gynaecology Drugs Product Landscape
4.2.1 Analysis by Therapy Type
4.2.2 Analysis by Indication
4.2.3 Analysis by Route of Administration
5 Global Gynaecology Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Gynaecology Drugs Market Segmentation
6.1 Global Gynaecology Drugs Market by Therapy Type
6.1.1 Market Overview
6.1.2 Hormonal Therapy
6.1.3 Non-Hormonal Therapy
6.2 Global Gynaecology Drugs Market by Indication
6.2.1 Market Overview
6.2.2 Gynaecology Cancers
6.2.3 Endometriosis
6.2.4 Female Infertility
6.2.5 Menopausal Disorder
6.2.6 Gynaecology Infections
6.2.7 Polycystic Ovary Syndrome (PCOS)
6.2.8 Contraception
6.2.9 Other Indication
6.3 Global Gynaecology Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Intravaginal
6.3.5 Others
6.4 Global Gynaecology Drugs Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacy
6.4.3 Retail Pharmacy
6.4.4 Online Pharmacies
6.4.5 Others
6.5 Global Gynaecology Drugs Market by End User
6.5.1 Market Overview
6.5.2 Hospitals
6.5.3 Specialty Clinics
6.5.4 Diagnostic Centers
6.5.5 Research Institute
6.5.6 Home Healthcare
6.5.7 Others
6.6 Global Gynaecology Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Gynaecology Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Gynaecology Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Gynaecology Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Gynaecology Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Gynaecology Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Eli Lilly and Company
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Pfizer, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Amgen Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 AstraZeneca
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 F. Hoffmann-La Roche Ltd.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Allergan Plc
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Bayer AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 AbbVie Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Lupin Pharmaceuticals Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Therapeutics MD Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Ferring Holding S.A.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Teva Pharmaceutical Industries Limited
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Addex Therapeutics Ltd.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Gynaecology Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us